Evolving Into a Biotech and Pharma Services Partner
October 2025, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced a strategic evolution of its corporate identity. Reflecting its expanded portfolio and deep alignment with the life sciences industry, the company is transitioning its core positioning from “Experts in Biophysics” to “Pharma Services.”
This rebranding marks a significant milestone in 2bind’s corporate journey, signaling the company’s evolution from a specialized technological provider into a fully integrated, strategic partner for biotech and pharmaceutical clients worldwide.
Key facts
- Strategic Pivot (Oct 2025): 2bind evolves corporate positioning from “Experts in Biophysics” to “Pharma Services.”
- Expanded Capabilities: Integration of advanced BSL1 & BSL2 cell culture laboratories for functional biological assays.
- Deeper Pipeline Insights: Portfolio expansion deeper into early-stage antibody developability and focused small molecule discovery.
- Tailored Biotech Solutions: Highly customized timelines, documentation, and pricing to maximize client funding and market visibility.
Driven by Portfolio Expansion and Development Focus
The transition to “Pharma Services” is driven by a substantial expansion of 2bind’s operational capabilities and a sharp refinement of its market focus. While biophysics remains a foundational pillar of the company’s scientific excellence, 2bind has increasingly integrated non-biophysical services to meet the complex demands of modern therapeutics.
Key drivers behind this strategic pivot include:
- Integrated Assay Capabilities: 2bind has successfully implemented state-of-the-art BSL1 and BSL2 cell culture laboratories, allowing the company to deliver comprehensive biological and biochemical functional assays alongside its core biophysical methodologies.
- Advancing Antibody Development: In the biologics sector, 2bind has progressively pushed further into the early-stage development pipeline, moving beyond late-stage analytics to actively support screening, developability, and early-stage lead selection.
- Targeted Small Molecule Portfolio: In small molecule drug discovery, 2bind continues to focus on early-stage campaigns, while tightly optimizing its portfolio and client infrastructure to match the stringent requirements of biotech startups and established pharma companies.
Tailored Solutions and Deep Molecular Understanding
For 2bind’s clients, with a particular focus on fast-moving biotech companies navigating the competitive pharmaceutical landscape, this corporate evolution brings distinct operational advantages.
The transition to “Pharma Services” translates into a highly tailored client experience. Deliverables such as service quality, documentation standards, project timelines, and commercial frameworks are now more closely customized to individual project milestones than ever before. Furthermore, 2bind’s scientific team has evolved to pair its renowned biophysical methodological expertise with a profound, mechanistic understanding of the molecules under evaluation.
“As our biotech clients compete for visibility, funding, and positioning within the broader pharmaceutical industry, they require more than just raw data,” said Cosimo Kropp, Co-CEO. “They need a partner who understands the therapeutic context of their molecules. Transitioning to ‘Pharma Services’ underscores our commitment to providing the actionable data packages, regulatory alignment, and fast turnaround times necessary to transform bold ideas into investable assets.”
The new corporate identity is effective immediately and will be integrated across 2bind’s digital platforms and service portfolios throughout the coming weeks.